.gif "IP Gear")
Excerpt from Gropep:
During the last 15 years, IGF-I has been administered to humans in a number of clinical trials to
evaluate its potential benefit in conditions of GH deficiency, diabetes, muscle wasting diseases,
multiple sclerosis, kidney disease and gastro-intestinal surgery. The length of treatment varied
from days to years and the doses ranged from 5μg/kg/day to 1500μg/kg/day. Routes of
administration have been subcutaneous or intra-venous. With very few exceptions, IGF-I was well
tolerated and no serious adverse events were reported. Reported side effects mimic those
observed with GH treatment but hypoglycaemia has not been a limiting factor. A number of
pathologies associated with a reduction in GH or circulating IGF-I results in one of the syndromes
of growth deficiency. Depending on the primary cause, children with short stature are treated with
GH or IGF-I.
Analysis of pharmacokinetic data in normal subjects is also important. A dose of 40μg/kg/day
resulted in an increase of 150μg/L above the starting baseline IGF-I concentration. The half-life in
the circulation was approximately 20h and suggested an endogenous production rate of IGF-I by
the body of 3 mg per day.
The potency difference between LONG®R3IGF-I and IGF-I is lower in vivo compared to cultured
cells. This means that the effective dose of LONG®R3IGF-I is similar to that of IGF-I administered
in clinical trials and as a therapeutic and that the potential for LONG®R3IGF-I to present a risk to
human health must be considered similar to that of IGF-I itself.
Assuming the above is true
we are using dosages of IGF-1LR3 20mcg-40mcg/shot whereas rIGF-1 which is suppose to be just as potent is given at 100-1000mcg/kg/day
Any thoughts?
During the last 15 years, IGF-I has been administered to humans in a number of clinical trials to
evaluate its potential benefit in conditions of GH deficiency, diabetes, muscle wasting diseases,
multiple sclerosis, kidney disease and gastro-intestinal surgery. The length of treatment varied
from days to years and the doses ranged from 5μg/kg/day to 1500μg/kg/day. Routes of
administration have been subcutaneous or intra-venous. With very few exceptions, IGF-I was well
tolerated and no serious adverse events were reported. Reported side effects mimic those
observed with GH treatment but hypoglycaemia has not been a limiting factor. A number of
pathologies associated with a reduction in GH or circulating IGF-I results in one of the syndromes
of growth deficiency. Depending on the primary cause, children with short stature are treated with
GH or IGF-I.
Analysis of pharmacokinetic data in normal subjects is also important. A dose of 40μg/kg/day
resulted in an increase of 150μg/L above the starting baseline IGF-I concentration. The half-life in
the circulation was approximately 20h and suggested an endogenous production rate of IGF-I by
the body of 3 mg per day.
The potency difference between LONG®R3IGF-I and IGF-I is lower in vivo compared to cultured
cells. This means that the effective dose of LONG®R3IGF-I is similar to that of IGF-I administered
in clinical trials and as a therapeutic and that the potential for LONG®R3IGF-I to present a risk to
human health must be considered similar to that of IGF-I itself.
Assuming the above is true
we are using dosages of IGF-1LR3 20mcg-40mcg/shot whereas rIGF-1 which is suppose to be just as potent is given at 100-1000mcg/kg/day
Any thoughts?
